|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 31/4995 | (2006.01) |
| A61P 25/34 | (2006.01) |
| (11) | Number of the document | 1448235 |
| (13) | Kind of document | T |
| (96) | European patent application number | 02785718.4 |
| Date of filing the European patent application | 2002-11-04 | |
| (97) | Date of publication of the European application | 2004-08-25 |
| (45) | Date of publication and mention of the grant of the patent | 2007-03-14 |
| (46) | Date of publication of the claims translation | 2007-06-26 |
| (86) | Number | PCT/IB2002/004612 |
| Date | 2002-11-04 |
| (87) | Number | WO 2003/045437 |
| Date | 2003-06-05 |
| (30) | Number | Date | Country code |
| 334652 P | 2001-11-30 | US |
| (72) |
AM ENDE, Mary Tanya, US
ROY, Michael Christopher, US
SMITH, Scott Wendell Pfizer Global Res. & Dev., US
WATERMAN, Kenneth Craig Pfizer Global Res. & Dev., US
MOSES, Sara Kristen Pfizer Global Res. & Dev., US
QUAN, Ernest Shing Pfizer Global Res. & Dev., US
|
| (73) |
Pfizer Products Inc.,
Eastern Point Road, Groton, CT 06340,
US
|
| (74) |
Marius JAKULIS - JASON,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | 5,8,14-triazatetraciklo[10.3.1.0(2,11).0(4,9)]-heksadeka-2(11)3,5,7,9-pentaeno geriamos kontroliuojamo atpalaidavimo farmacinės kompozicijos |
| ORAL CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF 5,8,14-TRIAZATETRACYCLO 10.3.1.0(2,11).0(4,9)]-HEXADECA-2(11)3,5,7,9-PENTAENE |
| Payment date | Validity (years) | Amount | |
| 2008-10-20 | 7 | 560.00 LTL |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2009-11-04 |